ArticleESMO open2023

Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.

B Doleschal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.